GW is one of the largest pharma companies pursuing cannabis-based medications. The company just reported encouraging Phase 3 results for Epidiolex, a cannabis-based drug designed to treat epilepsy in children. GW is anticipating FDA approval or rejection on Epidiolex by the first half of 2017. GW plans to submit Epidiolex to the European Union in the second half of 2017. For the time being, GW is not profitable. A full regulator approval in the U.S. and or Europe could change that. I consider this update to be excellent news for GW and shareholders.